Sepsis refers to a life-threatening organ dysfunction due to dysregulated host response to infection based on Sepsis 3.0 definition. Sepsis represents a global healthcare problem causing immense economic and societal burdens since it is the most common cause of in-hospital and intensive care unit mortality. Although the onset and progression of sepsis are substantially heterogeneous across disparate populations, it has been well documented that septic patients might experience one or more episodes of immunocompromised state in the development of sepsis, in association with increased incidence of nosocomial infection and poor outcome. However, precise yet feasible immune monitoring methods are currently lacking in clinical practice, rendering us unable to timely recognize the immunosuppressive status of septic patients. Given that, specific yet sensitive biomarkers are in urgent need to precisely monitor the immune functional status of patients with sepsis and septic shock, which also represent the prerequisite for the establishment and implementation of novel tailored immunotherapies.
Although great progress has been made in the identification of novel immune monitoring markers for septic patients, there are still major limitations inherent to the application of these means in clinical practice. The majority of biomarkers for evaluating and monitoring the immune status of septic patients remain relatively unspecific, which is unable to convey the entire magnitude of immune dysfunction and to distinguish critically ill patients with or without infections. While lymphocyte counts and circulating levels of multiple cytokines are relatively easy to obtain, their confounding factors remain intractable, hindering the broad use of these parameters. Of note, the lack of standardization of immunological measurement is a significant challenge, there is no accurate and consensual threshold for almost all flow cytometry-based leukocyte makers, including mHLA-DR, CD64, and PD-L1. Thus, the insufficient translation of many biomarkers and cutting-edge techniques used in pre-clinical studies may represent an additional obstacle.
Given the emergence of multi-omics-based techniques and the development of machine learning algorithm-based models, we are therefore seeking novel yet robust biomarkers and predictive models for the assessment and monitoring of immune status for septic patients.
The current Research Topic will focus on, but not limited to, the following themes:
? To identify novel biomarkers and cutting-edge approaches for assessing and monitoring the immune status of sepsis
? The clinical significance of immune-related indicators in the diagnosis and treatment of sepsis-induced immunosuppression
? The potential significance of immune monitoring and evaluation in guiding personalized immune-adjuvant therapies for septic complications
? Establishment of novel predictive models and stratification strategies in rapid recognition of septic patients at great risk of immune dysfunction
We welcome Original Research, Reviews, Mini-Reviews, Perspective, Protocols, and Case Reports for submission.
Sepsis refers to a life-threatening organ dysfunction due to dysregulated host response to infection based on Sepsis 3.0 definition. Sepsis represents a global healthcare problem causing immense economic and societal burdens since it is the most common cause of in-hospital and intensive care unit mortality. Although the onset and progression of sepsis are substantially heterogeneous across disparate populations, it has been well documented that septic patients might experience one or more episodes of immunocompromised state in the development of sepsis, in association with increased incidence of nosocomial infection and poor outcome. However, precise yet feasible immune monitoring methods are currently lacking in clinical practice, rendering us unable to timely recognize the immunosuppressive status of septic patients. Given that, specific yet sensitive biomarkers are in urgent need to precisely monitor the immune functional status of patients with sepsis and septic shock, which also represent the prerequisite for the establishment and implementation of novel tailored immunotherapies.
Although great progress has been made in the identification of novel immune monitoring markers for septic patients, there are still major limitations inherent to the application of these means in clinical practice. The majority of biomarkers for evaluating and monitoring the immune status of septic patients remain relatively unspecific, which is unable to convey the entire magnitude of immune dysfunction and to distinguish critically ill patients with or without infections. While lymphocyte counts and circulating levels of multiple cytokines are relatively easy to obtain, their confounding factors remain intractable, hindering the broad use of these parameters. Of note, the lack of standardization of immunological measurement is a significant challenge, there is no accurate and consensual threshold for almost all flow cytometry-based leukocyte makers, including mHLA-DR, CD64, and PD-L1. Thus, the insufficient translation of many biomarkers and cutting-edge techniques used in pre-clinical studies may represent an additional obstacle.
Given the emergence of multi-omics-based techniques and the development of machine learning algorithm-based models, we are therefore seeking novel yet robust biomarkers and predictive models for the assessment and monitoring of immune status for septic patients.
The current Research Topic will focus on, but not limited to, the following themes:
? To identify novel biomarkers and cutting-edge approaches for assessing and monitoring the immune status of sepsis
? The clinical significance of immune-related indicators in the diagnosis and treatment of sepsis-induced immunosuppression
? The potential significance of immune monitoring and evaluation in guiding personalized immune-adjuvant therapies for septic complications
? Establishment of novel predictive models and stratification strategies in rapid recognition of septic patients at great risk of immune dysfunction
We welcome Original Research, Reviews, Mini-Reviews, Perspective, Protocols, and Case Reports for submission.